181 related articles for article (PubMed ID: 35149566)
21. Elobixibat for the treatment of constipation.
Wong BS; Camilleri M
Expert Opin Investig Drugs; 2013 Feb; 22(2):277-84. PubMed ID: 23215781
[TBL] [Abstract][Full Text] [Related]
22. Effect of a Mediterranean diet intervention on gastrointestinal function in Parkinson's disease (the MEDI-PD study): study protocol for a randomised controlled trial.
Rusch C; Beke M; Tucciarone L; Dixon K; Nieves C; Mai V; Stiep T; Tholanikunnel T; Ramirez-Zamora A; Hess CW; Langkamp-Henken B
BMJ Open; 2021 Sep; 11(9):e053336. PubMed ID: 34551955
[TBL] [Abstract][Full Text] [Related]
23. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
[TBL] [Abstract][Full Text] [Related]
24. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.
Zangaglia R; Martignoni E; Glorioso M; Ossola M; Riboldazzi G; Calandrella D; Brunetti G; Pacchetti C
Mov Disord; 2007 Jul; 22(9):1239-44. PubMed ID: 17566120
[TBL] [Abstract][Full Text] [Related]
25. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
Rudling M; Camilleri M; Graffner H; Holst JJ; Rikner L
BMC Cardiovasc Disord; 2015 Jul; 15():75. PubMed ID: 26197999
[TBL] [Abstract][Full Text] [Related]
26. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
27. Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis.
Eguchi T; Yoshizaki T; Ikeoka S; Takagi M; Fujinami M; Matsuda T; Yamaguchi T; Nonaka T; Amioka S; Katayama N; Inoue K; Matsumoto M; Momose K; Sako T; Noda M; Morisawa T; Okada A
Dig Dis; 2021; 39(4):341-350. PubMed ID: 33142288
[TBL] [Abstract][Full Text] [Related]
28. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
[TBL] [Abstract][Full Text] [Related]
29. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation.
Mueller-Lissner S; Kamm MA; Wald A; Hinkel U; Koehler U; Richter E; Bubeck J
Am J Gastroenterol; 2010 Apr; 105(4):897-903. PubMed ID: 20179697
[TBL] [Abstract][Full Text] [Related]
30. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Misawa N; Higurashi T; Takatsu T; Iwaki M; Kobayashi T; Yoshihara T; Ashikari K; Kessoku T; Fuyuki A; Matsuura T; Ohkubo H; Usuda H; Wada K; Naritaka N; Takei H; Nittono H; Matsumoto M; Honda A; Nakajima A; Camilleri M
Aliment Pharmacol Ther; 2020 Sep; 52(5):821-828. PubMed ID: 32687674
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance.
Nakajima A; Fujimaki M; Arai Y; Emori K
J Neurogastroenterol Motil; 2022 Jul; 28(3):431-441. PubMed ID: 35799237
[TBL] [Abstract][Full Text] [Related]
32. Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation.
Yamamoto A; Kessoku T; Tanaka K; Takahashi K; Kasai Y; Ozaki A; Iwaki M; Kobayashi T; Yoshihara T; Misawa N; Ohkuma K; Fuyuki A; Higurashi T; Hosono K; Yoneda M; Iwasaki T; Kurihashi T; Nakatogawa M; Suzuki A; Taguri M; Oyamada S; Ariyoshi K; Kobayashi N; Ichikawa Y; Nakajima A
Contemp Clin Trials Commun; 2022 Aug; 28():100958. PubMed ID: 35812817
[TBL] [Abstract][Full Text] [Related]
33. Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs.
Taniguchi S; Yano T; Imaizumi M; Manabe N
Neurogastroenterol Motil; 2018 Dec; 30(12):e13448. PubMed ID: 30129138
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial.
Fukudo S; Endo Y; Hongo M; Nakajima A; Abe T; Kobayashi H; Nakata T; Nakajima T; Sameshima K; Kaku K;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):603-613. PubMed ID: 30056028
[TBL] [Abstract][Full Text] [Related]
35. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
36. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease.
Ondo WG; Kenney C; Sullivan K; Davidson A; Hunter C; Jahan I; McCombs A; Miller A; Zesiewicz TA
Neurology; 2012 May; 78(21):1650-4. PubMed ID: 22573627
[TBL] [Abstract][Full Text] [Related]
37. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.
Chey WD; Camilleri M; Chang L; Rikner L; Graffner H
Am J Gastroenterol; 2011 Oct; 106(10):1803-12. PubMed ID: 21606974
[TBL] [Abstract][Full Text] [Related]
38. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.
Simrén M; Bajor A; Gillberg PG; Rudling M; Abrahamsson H
Aliment Pharmacol Ther; 2011 Jul; 34(1):41-50. PubMed ID: 21545606
[TBL] [Abstract][Full Text] [Related]
39. Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study.
Payne T; Sassani M; Buckley E; Moll S; Anton A; Appleby M; Maru S; Taylor R; McNeill A; Hoggard N; Mazza C; Wilkinson ID; Jenkins T; Foltynie T; Bandmann O
BMJ Open; 2020 Aug; 10(8):e038911. PubMed ID: 32759251
[TBL] [Abstract][Full Text] [Related]
40. Probiotics for constipation in Parkinson's: A systematic review and meta-analysis of randomized controlled trials.
Yin S; Zhu F
Front Cell Infect Microbiol; 2022; 12():1038928. PubMed ID: 36439217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
